With robust antibody-based drugs directed to genetically validated targets, we will develop therapies that preserve vision to meaningfully impact people's lives.
We are advancing a pipeline directed to genetically validated ophthalmology targets. Building on insights into disease protection from naturally occurring genetic variants in the human population, we will change the treatment of ocular disease.
Broadwing’s team brings deep expertise in antibody discovery and development. We leverage Alloy Therapeutic’s industry-leading capabilities for antibody generation and develop therapies with a focus on maximizing the potential benefit to patients and providers.
Broadwing Bio was founded with a mission of ending blindness. To ensure our success, we will engage collaborative partners that share our vision to accelerate bringing medicines to patients in need.
Geographic Atrophy
Geographic Atrophy (GA) is an advanced form of Age-Related Macular Degeneration characterized by progressive irreversible vision loss for which there is no current treatment option. The atrophy is a loss of photoreceptors in the central visual field. As the progresslive atrophy encroaches on the fovea, central vision is impacted. This can lead to disability and blindness. The goal of interventional therapy for GA is to halt or slow the progression of photoreceptor loss, preserving vision.
Glaucoma
Glaucoma is a group of diseases impacting the optic nerve and involving the loss of retinal ganglion cells. Overproduction of aqueous humor or reduced outflow increases intraocular pressure, damaging the optic nerve and diminishing peripheral vision. The goal of interventional therapy for glaucoma is to prevent optic nerve damage and preserve vision.
Founder, CEO and board member, former senior director of molecular biology and metabolic disease at Genentech.
Founder, former head of project team leaders at Calico and head of technology platforms business development at Genentech.
Founder and scientific advisory board member, assistant professor in the Department of Biomedical Data Science at Stanford University.
Broadwing board member and chief strategy officer at Maze Therapeutics, as global franchise head for ophthalmology at Genentech and Roche helped develop faricimab and Port Delivery System with ranibizumab (PDS), novel treatment options for diabetic macular edema and neovascular age-related macular degeneration.
Board member and CEO of Alloy Therapeutics, co-founder of Adimab, Compass and Alector Therapeutics.
Scientific steering committee member and senior director, biology at Maze, former director of cardiorenal and fibrotic disease at Merck.
Scientific steering committee member and chief scientific officer at Alloy, former chief scientific officer at Compass Therapeutics and director of antibody engineering and head of strain engineering and open innovation at Adimab.
Scientific advisory board member, professor, Division of Biology and Biomedical Sciences, Washington University.
Scientific advisory board member, Joseph A.C. Wadsworth professor of ophthalmology, Duke University School of Medicine.
We are growing our team of drug discovery scientists who share our passion for developing medicines to end blindness. Please find our current openings here:
Scientist - Senior Scientist, Biology
If you are interested in learning more about our therapeutic programs and opportunities for partnering, please contact us at: